Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans lessened its stake in Vir Biotechnology, Inc. (NASDAQ:VIR) by 3.2% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 72,287 shares of the company’s stock after selling 2,401 shares during the period. Thrivent Financial for Lutherans owned 0.05% of Vir Biotechnology worth $643,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. XTX Topco Ltd bought a new position in Vir Biotechnology during the second quarter valued at about $431,000. Hsbc Holdings PLC boosted its position in shares of Vir Biotechnology by 148.3% during the 2nd quarter. Hsbc Holdings PLC now owns 46,222 shares of the company’s stock valued at $405,000 after purchasing an additional 27,605 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Vir Biotechnology by 10.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 637,486 shares of the company’s stock worth $5,673,000 after purchasing an additional 58,360 shares during the last quarter. WINTON GROUP Ltd raised its holdings in shares of Vir Biotechnology by 23.0% in the 2nd quarter. WINTON GROUP Ltd now owns 99,711 shares of the company’s stock worth $887,000 after purchasing an additional 18,668 shares in the last quarter. Finally, Federated Hermes Inc. lifted its stake in Vir Biotechnology by 19,327.1% during the second quarter. Federated Hermes Inc. now owns 300,148 shares of the company’s stock valued at $2,671,000 after purchasing an additional 298,603 shares during the last quarter. 65.32% of the stock is currently owned by institutional investors.

Vir Biotechnology Stock Down 1.1 %

Shares of NASDAQ:VIR opened at $7.32 on Wednesday. Vir Biotechnology, Inc. has a 12-month low of $7.12 and a 12-month high of $13.09. The firm has a market capitalization of $1.00 billion, a P/E ratio of -1.83 and a beta of 0.46. The firm has a fifty day moving average of $8.21 and a two-hundred day moving average of $9.12.

Vir Biotechnology (NASDAQ:VIR) last issued its earnings results on Thursday, August 1st. The company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.13). Vir Biotechnology had a negative net margin of 612.40% and a negative return on equity of 30.93%. The firm had revenue of $3.08 million during the quarter, compared to analysts’ expectations of $7.53 million. During the same quarter last year, the firm earned ($1.45) EPS. The business’s revenue for the quarter was down 19.0% compared to the same quarter last year. Equities research analysts expect that Vir Biotechnology, Inc. will post -3.26 earnings per share for the current fiscal year.

Insider Activity at Vir Biotechnology

In other Vir Biotechnology news, Director Janet Napolitano sold 12,190 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $7.80, for a total value of $95,082.00. Following the completion of the sale, the director now directly owns 11,616 shares of the company’s stock, valued at $90,604.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 15.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Barclays increased their price objective on Vir Biotechnology from $27.00 to $28.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. HC Wainwright restated a “buy” rating and issued a $110.00 target price on shares of Vir Biotechnology in a report on Tuesday, August 20th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Vir Biotechnology presently has a consensus rating of “Moderate Buy” and an average price target of $36.80.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).